← brief for 2026-10-23 · Slowing decline

Sodium-glucose cotransporter-2 inhibitors and mortality and liver-related outcomes in patients with alcoholic cirrhosis, type 2 diabetes, and obesity.

Article C Peer reviewed Observational

Key takeaways

This study looked at people with severe liver scarring, type 2 diabetes, and obesity. It compared those taking a diabetes drug called an SGLT2 inhibitor to those who were not. The group taking the drug had similar rates of death and liver problems. This shows a link to safety, but it is not proof of cause. The study used 5,128 matched pairs of patients.

Who did this work

Osman MM · Sims OT · Chiang DJ

Source

Article · PubMed, the drug frontier · 2026 Oct 22
https://pubmed.ncbi.nlm.nih.gov/42913941/